LPL Financial LLC Grows Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

LPL Financial LLC increased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 9.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,282 shares of the life sciences company’s stock after purchasing an additional 2,208 shares during the quarter. LPL Financial LLC’s holdings in Integra LifeSciences were worth $1,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. South Dakota Investment Council raised its holdings in shares of Integra LifeSciences by 36.0% during the fourth quarter. South Dakota Investment Council now owns 34,396 shares of the life sciences company’s stock valued at $1,929,000 after acquiring an additional 9,100 shares in the last quarter. Burney Co. purchased a new position in Integra LifeSciences during the fourth quarter valued at $228,000. Retirement Systems of Alabama increased its position in Integra LifeSciences by 0.7% during the 4th quarter. Retirement Systems of Alabama now owns 95,768 shares of the life sciences company’s stock valued at $5,370,000 after buying an additional 658 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Integra LifeSciences during the fourth quarter valued at $780,000. Finally, Synovus Financial Corp raised its position in shares of Integra LifeSciences by 3.3% in the 4th quarter. Synovus Financial Corp now owns 6,820 shares of the life sciences company’s stock worth $382,000 after purchasing an additional 217 shares during the last quarter. Hedge funds and other institutional investors own 87.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. JMP Securities decreased their target price on shares of Integra LifeSciences from $75.00 to $65.00 in a report on Thursday, April 27th. StockNews.com initiated coverage on Integra LifeSciences in a research report on Thursday, May 18th. They set a “buy” rating on the stock. Citigroup cut shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $59.00 to $39.00 in a report on Tuesday. TheStreet downgraded Integra LifeSciences from a “b-” rating to a “c+” rating in a research note on Monday. Finally, JPMorgan Chase & Co. cut Integra LifeSciences from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $56.00 to $43.00 in a research report on Wednesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $51.14.

Insider Buying and Selling

In other news, EVP Michael J. Mcbreen sold 1,843 shares of the business’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total value of $100,056.47. Following the sale, the executive vice president now directly owns 28,796 shares in the company, valued at approximately $1,563,334.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Lisa Evoli sold 3,767 shares of the firm’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $57.00, for a total transaction of $214,719.00. Following the completion of the sale, the executive vice president now directly owns 18,605 shares of the company’s stock, valued at approximately $1,060,485. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael J. Mcbreen sold 1,843 shares of the company’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total value of $100,056.47. Following the completion of the transaction, the executive vice president now directly owns 28,796 shares in the company, valued at approximately $1,563,334.84. The disclosure for this sale can be found here. 4.20% of the stock is owned by company insiders.

Integra LifeSciences Stock Down 1.7 %

IART opened at $38.48 on Friday. Integra LifeSciences Holdings Co. has a fifty-two week low of $38.13 and a fifty-two week high of $62.99. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.40 and a current ratio of 3.65. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 1.19 and a beta of 1.15. The firm’s fifty day moving average is $53.62 and its 200 day moving average is $55.03.

Integra LifeSciences (NASDAQ:IART – Get Rating) last announced its quarterly earnings data on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.74. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The business had revenue of $380.85 million during the quarter, compared to analyst estimates of $373.21 million. During the same period last year, the firm posted $0.74 EPS. The company’s revenue was up 1.1% on a year-over-year basis. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.42 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.